Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 220 Rectal Neoplasms 137 Stomach Neoplasms 95 Colonic Neoplasms 87 Pancreatic Neoplasms 82 Esophageal Neoplasms 71 Neoplasm Metastasis 58 Squamous Cell Carcinoma of Head and Neck 43 Head and Neck Neoplasms 42 Adenocarcinoma Of Esophagus 37 Neoplasms 36 Breast Neoplasms 35 Esophageal Squamous Cell Carcinoma 27 Carcinoma, Hepatocellular 22 Cholangiocarcinoma 21 Adenocarcinoma 17 Nasopharyngeal Carcinoma 16 Bile Duct Neoplasms 14 Gallbladder Neoplasms 13 Carcinoma, Squamous Cell 13 Biliary Tract Neoplasms 13 Anus Neoplasms 13 Urinary Bladder Neoplasms 11 Liver Neoplasms 10 Carcinoma 9 Nasopharyngeal Neoplasms 8 Colorectal Cancer Metastatic 8 Peritoneal Neoplasms 7 Recurrence 6 Ovarian Neoplasms 6

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumour × Fluorouracil × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡